Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Adavosertib · AZD-1775, MK-1775

Small molecule · Inhibitor of WEE1 · developed by ASTRAZENECA

Phase 2 Most advanced trial

AZN Developer

1 Registered trials

What is Adavosertib?

Adavosertib is a small molecule inhibitor of the tyrosine kinase WEE1. It prevents WEE1-mediated phosphorylation of CDK1, impairing the G2 DNA damage checkpoint and sensitizing p53-deficient tumor cells to DNA-damaging chemotherapy. It is studied in uterine cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-1775, MK-1775
Drug type: Small molecule
Targets: WEE1
Mechanism: Inhibitor of WEE1
Pathways: G2 DNA damage checkpoint, CDK1 phosphorylation, apoptosis
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: K2T6HJX3I3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03668340	Phase 2	Uterine Cancer	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Uterine Cancer

Other drugs acting on WEE1

ACR-2316 Phase 1/2 APR-1051 Phase 1 Potrasertib Investigational

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Adavosertib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z